Table 2.
Signature development characteristics for microRNA classifiers*
| First author (reference) | Cancer type | Outcome* | Training set sample size | No. of selected miRs | Expression increased | Expression decreased | Change in expression not stated | Variables assessed in training model | No. of miRs carried forward† /No. of selected miRs | Reason for not further testing all miRs |
| Zhi (58) | Astrocytoma | OS | 84 | 7 | 2 | 5 | 0 | NR | 3/7 | Not stated |
| Catto (20) | Bladder | P | 52 | 4 | 4 | 0 | 0 | Stage, T, grade | NA | NA |
| Dyrskjot (24) | Bladder | P | 106 | 4 | 4 | 0 | 0 | Stage, grade | NA | NA |
| Veerla (51) | Bladder | OS | 14 | 2 | 2 | 0 | 0 | NR | NA | NA |
| Foekens (26) | Breast | M | 38 | 4 | 1 | 0 | 3 | Age, menopausal status, tumor size, grade, mRNA levels | 4/4 | NR |
| Schepeler (46) | Colon | R | 37 | 2 | 0 | 2 | 0 | Age, sex, T, grade, histology | NA | NA |
| Schetter (47) | Colon | OS | 84 | 5 | 5 | 0 | 0 | Stage | 5/5 | NA |
| Cohn (22) | Endometrial | P, OS | 20 | 1 | 0 | 1 | 0 | NR | NA | NA |
| Hiroki (30) | Endometrial | R, OS | 21 | 6 | 0 | 6 | 0 | Stage, invasion | NA | NA |
| Guo (28) | Esophageal | R, OS | 30 | 2 | 2 | 0 | 0 | Age, sex, stage, tobacco, alcohol, T, N‡ | 2/2 | NA |
| Mathe (37) | Esophageal | OS | 76 | 1 | 1 | 0 | 0 | NR | 1/5 | Not stated |
| Ogawa (41) | Esophageal | OS | 30 | 6 | 6 | 0 | 0 | T, N | 1/6 | Not stated |
| Ueda (50) | Gastric | P, R, OS | 106§ | 14 | 6 | 5 | 3 | Stage | NA | NA |
| Haller (29) | GIST | P, R | 49 | 2 | 0 | 2 | 0 | NR | NA | NA |
| Budhu (16) | Hepatocellular | M, R, OS | 131 | 20 | 4 | 16 | 0 | NR | 20/20 | NA |
| Chung (21) | Hepatocellular | R | 23 | 7 | 6 | 1 | 0 | NR | NA | NA |
| Jiang (31) | Hepatocellular | OS | 25 | 19 | 0 | 0 | 19 | NR | NA | NA |
| Li (35) | Hepatocellular | OS | 75 | 1 | 0 | 1 | 0 | Cirrhosis | NR | NA |
| Cairo (17) | Hepatoblastoma | OS | 19 | 4 | 0 | 0 | 4 | NR | 4/4 | NA |
| Navarro (39,40) | HL | R | 84 | 1 | 0 | 1 | 0 | Age, sex, WHO status, disease extent | NA | NA |
| Calin (18) | Leukemia | P | 94 | 9 | 8 | 1 | 0 | NR | 9/9 | NA |
| Garzon (27) | Leukemia | R, OS | 122 | 5 | 5 | 0 | 0 | NR | 4/5 | PCR validation‖ |
| Marcucci (36) | Leukemia | R | 64 | 9 | 7 | 2 | 0 | NR | 9/9 | NA |
| Zhang (56) | Leukemia | OS | 29 | 7 | 3 | 4 | 0 | NR | NA | NA |
| Landi (32) | Lung | OS | 107 | 5 | 0 | 5 | 0 | Age, sex, histology, stage, smoking‡ | NA | NA |
| Patnaik (43) | Lung | R, OS | 77 | 6 | 0 | 5 | 1 | Sex | NA | NA |
| Raponi (44) | Lung | OS | 54 | 20 | 9 | 11 | 0 | NR | NA | NA |
| Yanaihara (53) | Lung | OS | 32 | 5 | 3 | 2 | 0 | Age, sex, stage, smoking | 2/5 | Not stated |
| Yu (55) | Lung | R, OS | 112 | 5 | 2 | 3 | 0 | NR | 5/5 | NA |
| Caramuta (19) | Melanoma | OS | 16 | 6 | 5 | 1 | 0 | NR | 2/6 | PCR validation‖, P value |
| Segura (49) | Melanoma | OS | 59 | 18 | 18 | 0 | 0 | Stage | NA | NA |
| Pass (42) | Mesothelioma | R, OS | 37 | 1 | 0 | 1 | 0 | NR | 1/1 | NA |
| Bray (14) | Neuroblastoma | R, OS | 96 | 15 | 15 | 0 | 0 | NR | 2/15 | Stratified by MYC status |
| Schulte (48) | Neuroblastoma | R, OS | 50 | 42 | 0 | 0 | 42 | NR | 42/42 | NA |
| Di Lisio (23) | NHL | OS | 22 | 12 | 1 | 0 | 11 | NR | 12/12 | NA |
| Lawrie (33) | NHL | R | 52 | 12 | 3 | 9 | 0 | NR | NA | NA |
| Zhao (57) | NHL | OS | 30 | 3 | 0 | 3 | 0 | NR | NA | NA |
| Eitan (25) | Ovarian | Rx, R, OS | 30§ | 5 | 4 | 1 | 0 | NR | NA | NA |
| Lee (34) | Ovarian | R | 33 | 2 | 0 | 2 | 0 | NR | NA | NA |
| Nam (38) | Ovarian | OS | 20 | 10 | 7 | 3 | 0 | NR | NA | NA |
| Yang (54) | Ovarian | R | 72 | 9 | 6 | 3 | 0 | NR | 1/9 | Plausibility, P value |
| Bloomston (13) | Pancreas | OS | 65 | 6 | 6 | 0 | 0 | NR | NA | NA |
| Schaefer (45) | Prostate | R | 75 | 15 | 5 | 7 | 3 | Stage, grade | 1/15 | P value |
*
GIST = gastrointestinal stromal tumor; HL = Hodgkin lymphoma; M = metastasis; miR = microRNA; N = node stage; NA = not applicable; NHL = non-Hodgkin lymphoma; NR = not reported; OS = overall survival; P = progression; PCR = polymerase chain reaction; PSA = prostate-specific antigen; R = recurrence; Rx = response to therapy; T = tumor stage; WHO = World Heath Organization.
†
Number of miRs carried forward to a test set of samples after classifier development.
‡
Only examined univariaby.
§
Averaged across outcome.
‖
Not specified why only this many were validated using PCR.